Multimodality treatment of metastatic renal cell carcinoma with immunotherapy and cytoreductive surgery is controversial. Especially the benefit of removing asymptomatic primary tumors in synchronous metastatic renal cell cancer has been debated since several nonrandomized, retrospective studies revealed an improved response to immunotherapy and prolonged survival following initial nephrectomy. Two recent randomized prospective trials both demonstrated a prolonged survival in those who were randomly assigned to undergo nephrectomy of the primary tumor prior to treatment with interferon alfa-2b than in those who were assigned to undergo treatment with interferon alfa-2b alone. In these trials the survival benefit was limited and strongly influenced by overall performance score. The timing of immunotherapy, either as neoadjuvant (prior to nephrectomy) or adjuvant treatment (following nephrectomy) in the multimodality approach of synchronous metastatic renal cell carcinoma remains controversial. Selection of patients, the possible mechanisms underlying the survival advantage of the combination of nephrectomy and immunotherapy, and the timing of the treatment modalities are discussed herein.
Introduction
Of the patients presenting with renal cell carcinoma (RCC), one third will have evidence of metastatic spread at the time of diagnosis, often with an asymptomatic primary tumor in place (1, 2). The median survival for patients with metastatic disease is disappointingly short with approximately 10 months. While metastatic RCC resists conventional chemotherapy, spontaneous regression of metastases is rare and has been observed following removal of the primary tumor (3, 4) . The emergence of immunotherapy for patients with metastatic renal cell cancer (5-7) has provided the basis for experimental strategies, which introduced new indications for cytoreductive surgery in this group of patients, even in those with an asymptomatic primary in situ. It is beyond the scope of this report to review and discuss the different immunotherapy regimens and to detail palliative nephrectomy for symptomatic metastatic kidney cancer. An overview of the current concepts and controversies in the treatment of patients with metastatic RCC and an asymptomatic primary tumor in place is given, and the timing of immunotherapy and nephrectomy in this multimodality treatment is discussed. who present with a symptomatic tumor and in whom palliative nephrectomy may be required in very rare cases (2, 11), benefit from removal of an asymptomatic primary was doubtful. From retrospective and non-randomized studies evidence emerged that patients with metastatic RCC, who were treated with interferon alfa or other cytokines, have improved survival if they first underwent nephrectomy as compared to historical controls (9, 12, 13) . Most protocols combining immunotherapy and cytoreductive surgery for patients with synchronous metastatic renal cell carcinoma aimed at nephrectomy prior to systemic treatment to reduce tumor load and symptoms originating from the primary. Even in patients with metastases responding to immunotherapy at extrarenal sites, a regression of the primary renal tumor is rarely seen (14-16) further supporting nephrectomy prior to systemic therapy. Additionally, some authors argue, that the primary tumor may act as an immunological sink rendering immunotherapy less effective with the primary in situ (8, 10), which is supported by animal studies (17). Table I summarizes the potential benefits associated with removal of the primary tumor as described in the literature.
Two randomized prospective phase III trials of the South Western Oncology Group (SWOG 8949) and the European Organization of Research and Treatment of Cancer Genitourinary Group (EORTC-GU 30947) had been initiated and recent results revealed a significant albeit limited benefit regarding time to progression and survival for nephrectomy and subcutaneous interferon alfa-2b as opposed to interferon alfa-2b alone (18, 19) . Subcutaneous interferon alfa-2b, like intravenous interleukin 2, has been shown to be effective in the treatment of metastatic RCC. Interferon alfa-2b can be administered on an out-patient basis and has less adverse effects than intravenous interleukin 2, which requires hospitalization. Therefore interferon alfa-2b has been favored as treatment in these randomized multicenter trials for its ease of application, while some argue that intravenous interleukin 2 may be more effective (7) . In contrast to malignant melanoma, specific tumor reaction antigens remain to be identified in RCC. It is believed that interferon alfa-2b potentially enhances antitumor activity by increasing HLA class-I expression, effector cell function (macrophages and killercells) and expression of adhesion molecules.
In both the SWOG and EORTC trial eligible patients had a histologically confirmed diagnosis of metastatic RCC with the primary tumor in place with metastases beyond the regional lymphatics; that is, metastatic disease involving a tumor of any size and any nodal status. The primary tumor was considered amenable to surgical removal by the attending surgeons. Patients with thrombosis of the inferior vena cava below the hepatic veins were not excluded. A performance status of 0 or 1 according to SWOG (18) or WHO (19) was required, and patients were excluded if they had received prior treatment with chemotherapy, hormonal therapy or immunotherapy.
In the SWOG study, the median survival of 120 eligible patients randomized for surgery followed by interferon was 11.1 months, versus 8.1 months in 121 patients assigned to interferon alone. In the smaller EORTC trial, 42 patients were assigned to surgery and interferon with a median survival of 17 months and 43 assigned to interferon alone with a median survival of 7 months.
There has been much debate regarding the difference in median overall survival between these trials. Both studies applied the same regimen of subcutaneous interferon alfa-2b (5 × 10 6 IU/m 2 three times a week) until progression of the tumor was detected and used the same inclusion criteria, surgical approach and controls. Both studies were performed as multi-institutional trials and before randomization patients were stratified according to performance status, presence or absence of lung metastases only, and the presence or absence of at least one measurable metastatic lesion in the region not to be resected, to better compare treatment outcome between the trials. Both trials used survival as the primary end point and identical criteria for assessing response and measuring disease. While the trial was designed by the SWOG with the one-sided stratified logrank test, the EORTC decided to compare response rates based on a two-sided Fisher's exact-test. Ultimately, the greatest difference lies in the power of both trials. In the SWOG study the required number of patients was enrolled (n = 246), while the EORTC could recruit 85 patients in three years.
The difference in median survival between both arms observed in each trial was independent of performance status, metastatic site and the presence or absence of measurable metastatic disease. When stratifying for performance status, however, the median survival of patients in the SWOG study with a performance status 0 was 17.4 months for surgery plus immunotherapy versus 11.7 months for immunotherapy alone. In addition to the fact that the power of the EORTC study is lower in comparison to the SWOG trial, it has therefore been argued, that the difference in median survival between the trials may be due to a bias caused by accrual of patients with a better performance status in the EORTC study (20) .
Selection may also be caused by a substantial difference in accrual time and participating centers. The SWOG planned to randomize 244 patients within a period of three years with 
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Tumor as source of ongoing metastasis.
Tumor may act as an immunological sink with immunosuppression.
Regression of the primary tumor following immunotherapy is rare.
Tumor burden with paraneoplastic effects contributing to cachexia and other symptoms with increase in performance after removal.
Prevention of local problems (bleeding, growth into adjacent organs and vessels).
one year of follow-up. Finally, it took seven years to enroll 246 patients from 80 participating institutions. In the smaller EORTC trial accrual time was three years for 85 patients from only three institutions. This difference reflects that there may have been an occult selection bias. The fact that in the SWOG study an average of 3 patients were recruited in each institution over a period of seven years suggests that either patients or doctors were reluctant to join the trial.
Despite these caveats, both trials are the only prospective randomized studies to date that show a significant albeit limited survival benefit for patients with metastatic renal cell carcinoma, and a good performance status, who undergo nephrectomy followed by immunotherapy with interferon alfa-2b.
Neoadjuvant Systemic Immunotherapy Followed by Nephrectomy
However, the timing of nephrectomy in this experimental approach remains controversial. Initial nephrectomy may have disadvantages such as shown in Table II . Initial removal of the tumor may result in clinical deterioration and delay of or exclusion from immunotherapy with subsequent disease progression. In larger series, 38% to 67% of patients with extensive metastatic disease eventually no longer met protocol requirements following cytoreduction, leading to exclusion from further immunotherapy (13, 21, 22) . These data from retrospective studies were not supported by the EORTC and SWOG studies, where the percentage was considerably lower, with only 2% being excluded in the SWOG study. Apparently, selecting patients with a good performance status results in a lower rate of exclusion from immunotherapy.
In light of the significant albeit limited survival benefit, a more important argument against initial nephrectomy may be that some patients will progress rapidly at metastatic sites despite initial surgery and adjuvant immunotherapy, raising doubt about the necessity of removal of an asymptomatic primary and subjecting patients to inappropriate surgery. The initial identical course of the survival curves of both treatment arms in both the EORTC and SWOG trial suggests, that approximately 20% of the patients die within the first 4 months, regardless of the treatment they were assigned to ( Figure 1 ). It may be argued that this identical drop is caused by patients with a reduced performance score, but there may be other underlying causes such as an aggressive tumor biol-ogy dooming the patients to progression at metastatic sites despite nephrectomy and immunotherapy. Whatever the factors involved, it reveals that 1/5 th of the patients do not benefit from the additional nephrectomy, as compared to the immunotherapy-only arm. Better patient selection is therefore desirable. To avoid the drawbacks of initial nephrectomy and to compensate for the lack of response in the primary tumor following immunotherapy, a combined approach may be neoadjuvant immunotherapy with the primary tumor in situ followed by delayed nephrectomy in those patients responding to or stable under systemic therapy. Patients not responding to initial immunotherapy may be spared an otherwise unnecessary intervention. Neoadjuvant immunotherapy may therefore be used to improve selection of patients, who are unlikely to benefit from additional surgery.
Furthermore, both the SWOG and EORTC study do not support the view, that the primary tumor acts as an immunological sink and that debulking by nephrectomy increases the efficacy of interferon. The rates of response to interferon alfa-2b in patients with measurable metastatic disease in the two treatment arms in the SWOG trial were equally low: 3.3% in the nephrectomy-plus-interferon group and 3.6% in the interferon-only group (23). However, the dose of interferon alfa-2b has to be considered low and may not be optimal. The rea- 
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Morbidity associated with major surgery leading to reduction of performance and exclusion from immunotherapy. • Progression of distant metastasis in the recovery period.
Immunosuppression as a consequence of nephrectomy. • Immune cells infiltrating in the primary tumor, that may be activated by neoadjuvant immunotherapy, are removed. Figure 1 : The survival curves of the SWOG study (a) and the EORTC trial (b). The red line indicates that approximately 20% of the patients died rapidly within the first months regardless of the treatment they were assigned to. Curve a) reprinted with permission from (18) sons for the apparent survival benefit in the nephrectomyplus-interferon arm therefore remain unknown and may be due to several factors. Table III summarizes mechanisms potentially underlying the survival advantage. Experimental findings, such as an association with elevated serum C-reactive protein levels (24) or a potential antineoplastic effect of nephrectomy-induced azotemia (25) are currently discussed. Elevated C-reactive protein levels prior to nephrectomy may reflect an inflammatory response in the tumor as source of an excretion of proliferative factors such as interleukin-6 or transforming growth factor-β and nephrectomy may decrease the amount of these factors. Elimination of paraneoplastic effects of the primary tumor and, ultimately, occult patient selection criteria unconsciously applied by doctors and patients when inviting or agreeing to enter the trial (23) are possible other factors involved. Additionally, a recent retrospective study of 434 patients with metastatic RCC revealed in a multivariate analysis, that patients with more than one metastatic site involved had a lower response rate to adjuvant immunotherapy following nephrectomy of the primary tumor and a significantly shorter survival than patients with one metastatic site. Survival in patients with single metastatic sites but at different locations was similar (26). Eligible patients in the SWOG and EORTC study had to have a histologically confirmed metastatic renal cell carcinoma with a resectable primary tumor in place and metastases beyond the regional lymphatics and the observed survival benefit in the SWOG study was independent of the location of metastatic sites. However, both trials did not stratify for the number of metastatic sites or overall tumor burden, and the impact of this factor on the survival advantage observed in the nephrectomy-plus-immunotherapy arm therefore remains unsolved.
On the contrary, now that improving efficacy of adjuvant interferon by initial nephrectomy is less likely, it is of great interest whether the immune system will ultimately be compromised by initial surgery. It has been described that nephrectomy reduced part of the immune response and that pre-operative interleukin-2 may prevent postoperative immune suppression (27).
To date, only a few retrospective studies addressed the combination of initial immunotherapy followed by cytoreductive surgery (15, 16, (28) (29) (30) . These studies were not designed to investigate the role of neoadjuvant immunotherapy in identifying patients who may benefit from subsequent surgery.
We therefore initiated a prospective pilot study to assess the feasibility of immunotherapy prior to nephrectomy in patients with metastatic renal cell cancer and the primary in situ and to evaluate the role of immunotherapy as selection for cytoreductive surgery (31). Sixteen patients with synchronous extensive metastases at more than one metastatic site with a WHO performance score 0 or 1 were treated with the primary tumor in place and were evaluated with regard to age, sex, sites of extrarenal disease, morbidity, response, nephrectomy rate, time to progression and overall survival. Immunotherapy consisted of 2 courses of subcutaneous lowdose IL-2 4 MIU/m 2 , GM-CSF 2.5 µg/kg and interferon alfa-2b (Schering-Plough) 5 MU fixed dose on day 1-13 and 22-34 (32). The rationale for this regimen was to activate and expand the three arms of the immune response (T-and natural killer-cell response, antigen-presentation by dendritic cells and increase of effector cell function).
Patients with either partial remission (PR) or stable disease (SD) at metastatic sites underwent nephrectomy, followed by a 3rd and 4th course, whereas patients progressing at extrarenal sites during immunotherapy were excluded from surgery. No response was seen in the primary tumors but none of the tumors became irresectable following immunotherapy. With regard to extrarenal sites SD was noted in 9 cases, PR in 2 and progressive disease (PD) in 5. Eleven patients underwent nephrectomy. All patients with PD died after a median overall survival of 3 (2-7) months versus 11.5 (4-22) months in those who underwent nephrectomy. In none of the 5 patients with PD death was related to local tumor growth or symptoms originating from the primary. Four patients are still alive at 10, 12, 18 and 19 months. Median duration of response was 6 (2-10) months. The data from this prospective trial suggest, that failure to respond to initial immunotherapy may be appropriate to identify those patients who will not benefit from additional nephrectomy, though our study is underpowered to give a definite answer yet. However, conclusions can be drawn from this study supporting a trial to assess the role of initial versus delayed nephrectomy in combination with immunotherapy. In this pilot study 5/16 patients (31%, with a 95% Clopper-Pearson confidence interval (C-P CI) of 11-59%) were spared from surgery if progression during initial immunotherapy was used as selection. Thus, in a larger comparable group of patients, minimally 10% and maximally 60% can be expected to be excluded from an otherwise unnessecary intervention if progression occurs with upfront immunotherapy. The median overall survival of patients who underwent cytoreductive surgery following immunotherapy is comparable to that of larger randomized studies (e.g. SWOG-trial, median overall survival 11.1 months in the combined arm). None of the 11 patients who ultimately were elected for nephrectomy became locally inoperable during the time they received initial immunotherapy (95% C-P CI of 0-28%). This excludes that more than 30% of the patients are put at risk to progress to locally irresectable primary tumors while receiving initial immunotherapy. These data have encouraged us to initiate a randomized trial to evaluate the timing of nephrectomy in combination with immunotherapy in patients with extensive metastatic renal cell carcinoma, with emphasis on quality of life in the first place and secondly on response and survival.
Conclusions
Two prospective randomized trials revealed a limited survival benefit for patients with metastatic renal cell cancer and an asymptomatic primary in situ following initial nephrectomy and immunotherapy versus immunotherapy alone. The increase in median survival was 10 months in the EORTC study and 3 months in the SWOG trial and this difference is generally attributed to a difference in overall performance of the patients at entry. When stratifying the patients from the SWOG study to a performance status 0 the increase in median survival almost equalled the EORTC data. The mechanisms underlying the survival advantage remain unknown. The timing of nephrectomy or immunotherapy in multimodality treatment of metastatic RCC remains controversial, as no data from prospective randomized trials of initial versus delayed nephrectomy with adjuvant or neoadjuvant immunotherapy exist to date. From the available data of the EORTC and SWOG study it is conceivable, that approximately 20% of the patients will not benefit from the additional nephrectomy and deteriorate rapidly, despite the combined approach, and will therefore undergo an unnecessary and morbid intervention. Neoadjuvant immunotherapy followed by delayed nephrectomy in non-progressing patients with a good performance score may be an alternative allowing for better patient selection. Evidence from retrospective studies and our own prospective trial suggests that this approach is feasible and does not increase the risk of delaying surgery to a point after which any intervention would be inappropriate due to local tumor progression.
Despite reported encouraging long term results of immunotherapy combined with nephrectomy, it has to be born in mind that the treatment of patients with metastatic renal cell cancer essentially remains palliative and thus not only duration of survival, but quality of life is of importance in assessing future trials. Given the current evidence, patients with metastatic RCC should be continued to be treated in trials. Additionally, it is desirable that, as the SWOG and EORTC trials are the only prospective randomized studies in this setting, initial nephrectomy followed by interferon alfa-2b should be the control arm in future trials.
In the absence of a suitable trial, initial nephrectomy and adjuvant immunotherapy may be offered to carefully selected patients with a good performance score. It is, however, important that the patient has been informed about the limit-ed survival benefit. In our view, neoadjuvant immunotherapy followed by delayed nephrectomy in patients without progression constitutes an alternative, with the relative benefit of excluding patients who will rapidly progress from the morbidity of additional surgery.
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